Immunotolerance in Endometrial Cancer and at the Maternal-fetal Interface: Immunological Profiling of the Tumor Microenvironment in Risk Stratification of Recurrence

Save

Report Abuse

Description

This pilot/exploratory study will be configured as a non-retro-prospective study interventional on endometrial tissue samples taken from surgically treated patients at the Regina Elena National Cancer Institute, IRE - IFO and stored at the Biobank of same Institute (BBIRE) (cohort 1) and on samples of decidualized endometrium and trophoblast from patients with ongoing spontaneous abortion treated surgically at the UOC of Gynecology ed Obstetrics of the Federico II University Polyclinic of Naples (cohort 2)

Targeted Conditions

Study Overview

Start Date
December 13, 2022
Completion Date
December 13, 2025
Enrollment
30
Date Posted
February 8, 2024
Accepts Healthy Volunteers?
No
Gender
Female

Locations

Full Address
"Regina Elena" National Cancer Institute
Rome 00144, Italy

Eligibility

Study Population
Oncology patients who have undergone or will undergo to surgery. And patients with ongoing miscarriage who do will undergo surgery.
Minimum Age (years)
18
Eligibility Criteria
Inclusion Criteria:

Cohort 1: Oncology patients

Age >18 years
Histological diagnosis of endometrial hyperplasia with and without atypia, endometrial carcinoma endometrioid histotype at any stage of the disease (FIGO I-IV), patients subjected to hysterectomy for benign extra-endometrial pathology, patients with recurrence/metastasis from endometrioid endometrial carcinoma who undergo surgery;
Adequate biological material to be able to carry out the planned analyses;
Written informed consent (only for patients in the prospective part and/or in follow up/traceable);
For the retrospective part: availability of samples adequately stored at the biobank of the Institute and availability of data relating to follow-up (at least 36 months).

Cohort 2: Patients with ongoing spontaneous abortion

Age >18 years;
Diagnosis of ongoing spontaneous abortion which is subjected to an instrumental review procedure of the uterine cavity, under hysteroscopic guidance;
Adequate biological material to be able to carry out the analyzes previously described;
Written informed consent.

Exclusion Criteria:

Comorbidities not controlled with adequate medical therapy;
Infections of the endometrial cavity (pyometra);
Synchronous tumors;
Neoadjuvant treatments;
Previous radiation treatments on the pelvic region.

Study Contact Info

Study Contact Name
Valentina Bruno, Doctor
Study Contact Email
Study Contact Phone
nd

Contact Listings Owner Form

Immunotolerance in Endometrial Cancer and at the Maternal-fetal Interface: Immunological Profiling of the Tumor Microenvironment in Risk Stratification of Recurrence 0 reviews

Write Your Review

There are no reviews yet.

Write Your Review

Your email address will not be published. Required fields are marked *

Other Details

FDA Regulated Drug?
No
FDA Regulated Device?
No
Detailed Description
For the experiments proposed in the project the following will be used:

Court 1: tissue samples (healthy and tumor taken from the same patient) collected at the Institute's Biobank (starting from 2017) (retro-prospective); Court 2: tissue samples (decidualized endometrium and trophoblast taken from it patient) which will be collected at the Gynecology and Obstetrics Unit of the Polyclinic Federico II University of Naples (prospective) and transfer to the Regina National Cancer Institute Elena, IRE-IFO.

Clinical data

The following data will be collected for each patient:

Age, ethnicity, parity, luxury habits, level of education, marital status, height, weight, index of body mass
Data on previous clinical history, previous gynecological-obstetric pathologies and any treatments, current comorbidities and medical therapies

For Cohort1 patients only:

Data relating to the neoplastic pathology: histotype, grading, FIGO stage
Data on oncological follow-up: any intra- or post-operative complications, any therapies adjuvants, type and data of any recurrence/metastasis, type of treatment if any recurrence, date and manner of death.
NCTid (if applicable)
NCT06250010